AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02123212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHR Alert
Description: EHR include a Best Practice Alert (BPA) prompting the Medical Assistant and/or clinican to order a Hepatitis C lab test for patients in the birth cohort.
Study NCT01986010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160 Low Dose IM
Description: V160 administered as a 0.75 mL intramuscular injection
Study NCT01986010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160 Medium Dose IM
Description: V160 administered as a 0.75 mL intramuscular injection
Study NCT00212134 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lens correction of aphakia
Description: optical correction of infant surgical aphakia with Contact lens
Study NCT00212134 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraocular lens implantation
Description: optical correction of surgical aphakia with intraocular lens
Study NCT01986010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160 High Dose IM
Description: V160 administered as a 0.75 mL intramuscular injection
Study NCT01986010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM
Description: V160 plus MAPA administered as a 0.75 mL intramuscular injection
Study NCT01058499 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction Program (MBSR)
Description: Traditional eight-week MBSR Program.
Study NCT04313205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JKB-122 in capsule or tablet form
Description: JKB-122 is a TLR4 antagonist and will be administrated in capsule or tablet form
Study NCT01109524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Vial, Intravenous, 400mg/m², week 1, then 250mg/m², Weekly, Until Progressive Disease (PD)/ Toxicity/Pt-PI Decision
Study NCT01109524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Vial, Intravenous, 80mg/m², Day 1 of each 21 day cycle, Maximum 6 cycles
Study NCT01109524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vial, Intravenous, 25 mg/m², Day 1 and 8 of each 21 day cycle, Maximum 6 cycles
Study NCT00003612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Study NCT00003612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00003612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT01849978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Newsletter about physical activity and breast cancer survivors
Description: Both groups will receive a newsletter that covers: 1) the recommendation to pursue at least 150 mins/week of moderate to strenuous intensity PA, 2) the benefits of PA specific to breast cancer survivors (e.g., reducing in death and breast cancer recurrence), and 3) their total minutes of moderate to strenuous intensity PA and how this compares to the recommendation.
Study NCT01849978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Changing your habits brochure
Description: Both groups will receive the brochure titled Changing Your Habits: Steps to Better Health, developed by the NIH, that describes, based a person's stage of change, the benefits of PA, how to overcome common barriers to PA, and if ready, how to plan for PA.
Study NCT01849978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tips for making exercise enjoyable and personally-valued
Description: Participants will get a list of potentially enjoyable activities and a space to list other activities after they consider aspects that can make events fun/interesting.13 Aspects to consider include: location (indoors vs. outdoors, the latter which may appeal to some), hobbies that can involve PA (e.g., sports, dancing), whether the activity is made more enjoyable by having it performed by oneself or with others (e.g., team activities vs. individual activities); what valued outcomes may be achieved (e.g., sense of competence, pride, better health, body image), accompanying activities that are pleasant (e.g., listening to music), etc.
Study NCT01849978 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Testimonials from breast cancer survivors
Description: Participants will get two to three testimonials of actual breast cancer survivors. These testimonials will include story-like details of what these survivors find enjoyable about exercising and what they have done to make exercise enjoyable.
Study NCT01923480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15% CLINISOL - Sulfite-free (Amino Acid) Injection
Study NCT03169894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDGN-002
Description: MDGN-002 is a fully human IgG4 monoclonal antibody specific to human LIGHT.
Study NCT01740531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S-303 Treated Red Blood Cells (RBCs)
Study NCT01740531 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional, untreated Red Blood Cells
Study NCT02903199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein
Description: Whey protein (18 g) administered immediately prior to breakfast and lunch meals.
Study NCT02903199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolysed Protein
Description: Hydrolysed whey protein (19.1 g) administered immediately prior to breakfast and lunch meals.
Study NCT02903199 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intervention administered immediately prior to breakfast and lunch meals.
Study NCT01871675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-145
Study NCT01871675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT02085213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: Matched placebo
Study NCT03357913 — intervention group
Intervention type: OTHER
Intervention: Lung transplantation
Description: To estimate the incidence of non-respiratory co-morbidities after lung transplantation between 2004 and 2014 in the cohort of patients with cystic fibrosis grafted in the Rhône-Alpes region
Study NCT02368080 — intervention group
Intervention type: DEVICE
Intervention: Comparison of two MBWN2 devices : EasyOne Pro Lab versus Exhalyzer D
Description: Healthy and Cystic Fibrosis participants will perform the same day MBWN2 tests in duplicate with each device.
Study NCT04115618 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Simultaneous integrated boost intensity-modulated chemoradiotherapy
Description: Using IMRT technology, two fields are irradiated synchronously, prescription radiation dose: 50.4 Gy/28F in PTV-C, 1.8 Gy per fraction; 63 Gy/28F in PTV-G, 2.25 Gy per fraction. Six times of concurrent DP week regimen chemotherapy: cisplatin 20mg/m2 qw plus docetaxel 20mg/m2 qw.
Study NCT03620812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: rapeseed or soy protein or no protein
Description: 25g rapeseed protein in comparison to 25g soy protein or no protein - dosage of 25 g per day
Study NCT03620812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: rapeseed or soy protein or no protein
Description: 25g rapeseed protein in comparison to 25g soy protein or no protein - dosage of 25 g per day
Study NCT03620812 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: rapeseed or soy protein or no protein
Description: 25g rapeseed protein in comparison to 25g soy protein or no protein - dosage of 25 g per day
Study NCT04218799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Mupirocin and Topical Chlorhexidine
Description: Antimicrobial antiseptic skin cleanser (4% chlorhexidine) for daily use on Day 1, 3 and 5 of Week 8 of the study. BACTROBAN NASAL ointment (mupirocin calcium ointment, 2%) for use intranasally twice-daily on Day 1, 2, 3, 4 and 5 of Week 8 of the study.
Study NCT02086721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19-IL2
Description: Patients receive a schedule of 1 x 30 Gy, 3 x 15-20 Gy; 5 x 12 Gy; 8 x 7.5 Gy; to the 80 % or 100 % isodose.~Step -1: Toxicity of 10 Mio IU of L19-IL2 (n=3-6)10 Mio IU of L19-IL2 (max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21. Step 1: Toxicity of 15 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.~Step 2: Toxicity of 22.5 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle.~Step 3: Expansion cohort of the maximally tolerable dose (n=10) Administration of the maximally tolerable dose of L19-IL2(max. 6 cycles) via i.v. bolus injection.~Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle.
Study NCT02308176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APP + health advice
Description: health advice and reinforcement to it
Study NCT02308176 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: health advice
Description: health advice
Study NCT01238406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD-logic Artificial Pancreas (MDLAP)
Description: Treatment with the closed loop MD-logic Artificial Pancreas(MDLAP)System
Study NCT01238406 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment with insulin pump
Description: Standard treatment with sensor augmented pump therapy
Study NCT00426556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus (RAD001) was supplied as tablets in 3 different dosage strengths, 2.5, 5, and 10 mg. The drug was packaged in blisters containing 10 tablets per blister. Blisters and packaging labels were compliant with local regulations and were printed in local language.
Study NCT01986010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160 High Dose plus MAPA 225 µg /dose IM
Description: V160 plus MAPA administered as a 0.75 mL intramuscular injection
Study NCT01986010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160 Maximum Dose IM
Description: V160 administered as a 0.75 mL intramuscular injection
Study NCT01986010 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IM
Description: Placebo administered as a 0.75 mL intramuscular injection
Study NCT01986010 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V160 Medium Dose ID
Description: V160 administered as a 0.1 mL intradermal injection
Study NCT03533010 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ca500mg
Description: subjects receive a daily dose of 500mg elemental calcium
Study NCT03533010 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VitD800IU
Description: subjects receive a daily dose of 800IU VitD3
Study NCT03533010 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subjects receive placebo tablet
Study NCT04276025 — intervention group
Intervention type: OTHER
Intervention: Clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome
Description: Retrospective analysis of clinical routine F18-FDG-PET/CT, molecular pathology and clinical outcome data.
Study NCT00560300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 alpha D2
Description: Vitamin D sterol
Study NCT00560300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1,25 dihydroxy vitamin D3
Description: Active vitamin D sterol
Study NCT00560300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer HCl
Description: Phosphate binder
Study NCT00560300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Phosphate binder
Study NCT01328743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention
Description: 3 sessions of individual face-to-face counseling at baseline, 3 and 6 months. Sessions are motivationally focused including discussion of pros and cons of drinking and feedback on health and its relation to heavy drinking
Study NCT00426556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Commercially-available trastuzumab was used in this study. A 4 mg/kg loading dose was administered, intra-venous (IV), over 90 minutes on Day 1 (if patient was not already receiving trastuzumab); this was followed by weekly trastuzumab 2 mg/kg IV administered over 30 minutes. For patients who continued to receive trastuzumab and everolimus after completion/discontinuation of chemotherapy in the core treatment phase, trastuzumab may have been administered once every 3 weeks at a dose of 6 mg/kg. PT = Paclitaxel \& Trastuzumab
Study NCT00426556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Commercially-available paclitaxel was used in this study. Paclitaxel infusion was administered on Days 1, 8, and 15 of each 28-day cycle, after administration of trastuzumab. Paclitaxel (80 mg/m2) was administered as a 60-minute continuous IV infusion after standard premedication. Patients received paclitaxel for 6 cycles. At the investigator's discretion, treatment with paclitaxel could continue beyond 6 cycles.
Study NCT03334006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentaglobin®/Standard of Care
Description: Standard of Care treatment + Pentaglobin®
Study NCT02525926 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: denervation
Description: The examination proceeds under rigorous aseptic technique. Femoral, jugular or brachial venous access will be performed. A flexible catheter is first introduced across a 7-Fr venous introducer, and passed through the right heart chambers toward the origin of the pulmonary arteries. The pressures in the right heart chambers and the pulmonary artery will be measured. At the end of the examination, the catheter is removed, a dressing is applied and the venous puncture is compressed by hand.
Study NCT02525926 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham procedure
Description: Right heart catheterism is mandatory in PAH patients care (for diagnosis and during follow-up) and will serve as a  sham  procedure. A usually performed and after a venous punction, cardiac outpout and pulmonary artery pressures will be recorded.~Acoustically isolated headphones will be given to patients during the procedure in order to assure simple-blind during the study.
Study NCT04097821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg tablets for oral use
Study NCT01871675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Study NCT03384238 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV
Study NCT04097821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib
Description: 5 mg tablets for oral use
Study NCT04097821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Siremadlin
Description: 10 mg, 20 mg, or 40 mg capsules for oral use
Study NCT04097821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizanlizumab
Description: 100 mg/mL concentrate for infusion for intravenous use
Study NCT02650791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study NCT04097821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sabatolimab
Description: 100 mg/mL or 400 mg/4 mL concentrate for infusion for intravenous use
Study NCT04097821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rineterkib
Description: 100 mg capsule for oral use
Study NCT04097821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIS793
Description: 700 mg/7 mL concentrate for intravenous use
Study NCT03442348 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid
Description: Participants in the bottom median of dietary fibre intake (\<15 g per day) will be randomised into one of two arms. Participants in the second arm (N>32) will be required to take one 500mg capsule of Omega 3 along with a meal daily for 6 weeks.
Study NCT03442348 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin fibre
Description: The participants in the control arm (N>32) will be asked to take 20 g of fibre (resistant starch + inulin) per day that are known favour production of SCFAs in the colon for a period of 6 weeks. The inulin powder will be provided in pre-weighed sachets containing 10g each which can be taken mixed in water or a suitable beverage of choice taken twice (morning and evening) per day.
Study NCT01986010 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ID
Description: Placebo administered as a 0.1 mL intradermal injection
Study NCT05649449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Directed Care
Description: Participants meet with self-directed care program staff called brokers to receive a program orientation, share perceptions of their current life situation and mental health status, and review past year behavioral health service use as well as participants' views of service helpfulness. This culminates in participants' choice of recovery goals and development of an individual budget to pay for for services and material goods directly related to recovery goals. After budget approval by the program supervisor, brokers make purchases. At quarterly meetings, brokers and participants discuss the latter's progress toward recovery goals and create the next quarter's budget. After receiving 12 months of SDC services, participants are helped to transition back to usual community mental health services.
Study NCT05649449 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Services as usual
Description: Participants receive usual outpatient psychiatric care delivered at community programs from which the person can choose from an array of services negotiated with the state mental health authority.
Study NCT00795808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500mg tds for 6 months
Study NCT00795808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One tablet tds for 6 months
Study NCT00795808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + Clomiphene
Description: 500mg tds + Ovulatory dose for 6 months
Study NCT00795808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene
Description: Ovulatory dose for 6 months
Study NCT03632317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: 30 mg/m\^2
Study NCT03632317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 3.0 mg/m\^2
Study NCT00941057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium
Description: Oral, single dose, 2 mg EV + 3 mg DNG + 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
Study NCT00941057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG)
Description: Oral, single dose, 2 mg EV + 3 mg DNG washout phase between treatments: at least 7 days
Study NCT00941057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAY 86-7660,levomefolate calcium
Description: Oral, single dose, 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
Study NCT00302549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FK506
Description: FK506,0.1mg/kg/d
Study NCT03716076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: 50 mcg or 100 mcg bolus of carbetocin
Study NCT01918826 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Study NCT01918826 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS
Study NCT00690326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral change communication to promote physical activity
Description: treatment type: behavioral (lifestyle counseling)~treatment name: behavioral change communication to promote physical activity
Study NCT00690326 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral change communication to promote physical activity
Description: Arm B given placebo comparator ie pamphlet~Audiovisual module Physical activity frequency questionnaire
Study NCT01479257 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: 36 questionnaires at the first visit (a total of 474 questions) and 25 questionnaires at the second visit (a total of 278 questions), taking about 60 to 90 minutes to complete each visit.
Study NCT01479257 — intervention group
Intervention type: DEVICE
Intervention: Accelerometer
Description: Small device worn on the hip for 7 consecutive days that measures physical activity.
Study NCT01479257 — intervention group
Intervention type: DEVICE
Intervention: Smart Phone
Description: Questions on smart phone up to 5 times a day for 7 days taking about 5-7 minutes to complete each time.
Study NCT01900665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solanezumab
Description: Administered Intravenously (IV)
Study NCT01900665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV